313 results about "Phenyl-naphthylene" patented technology

The invention discloses phosphorescent luminescent materials and a preparation method and application thereof. The invention is characterized in that the phosphorescent luminescent materials are red light materials containing a metal iridium complex; a structural general formula of the phosphorescent luminescent materials is shown in the specification; and in the structural general formula, R1 and R2 are independently one of alkyl, phenyl, halogen-substituted phenyl, alkyl-substituted phenyl, naphthyl, anthryl, a halogen substituent, methoxy, phenoxy, cyano-substituted carbazolyl, substituted N-phenylcarbazolyl, quinolyl, thiazolyl, thienyl, an aromatic amino group, a group with an azole structure, an aromatic heterocyclic radical, a substituted aromatic heterocyclic radical and a silicon alkyl substituent respectively. The phosphorescent materials have high luminous efficiency; and the high luminous efficiency shows that the compounds can be taken as luminescent materials or main luminescent materials and applied to electroluminescent devices. Through data test and comparison, the materials are organic electroluminescent materials which have excellent performance and a good prospect, and particularly are phosphorescent red light materials which have good performance; and moreover, a method for synthesizing the luminescent materials is simple and low in cost.

Compounds of the formula I:including any possible stereoisomers thereof, wherein:R1 is hydrogen or halo;R4 is a monophosphate, diphosphate or triphosphate ester; or R4 is a group of formulaR7 is optionally substituted phenyl; naphthyl; indolyl or N—C1-C6alkyloxycarbonyl-indolyl;R8 is hydrogen, C1-C6alkyl, benzyl;R8′ is hydrogen, C1-C6alkyl, benzyl; orR8 and R8′ together with the carbon atom to which they are attached form C3-C7cycloalkyl;R9 is C1-C10alkyl, benzyl, or optionally substituted phenyl;or a pharmaceutically acceptable salt or solvate thereof.pharmaceutical formulations and the use of compounds I as HCV inhibitors.

The use of an additive including a mixture of oligomers that is produced from the reaction of aromatic amines chosen from:(i) the reaction with one another of diphenylamine (DPA) compounds of formula (I) below:wherein the groups R1 and R2 stand for, independently of one another, a hydrogen or a linear or branched alkyl group having from 1 to 30 carbon atoms, advantageously from 4 to 12 carbon atoms,(ii) the reaction with one another of phenyl-α-naphthylamine (PAN) compounds of formula (II) below:wherein the group R3 stands for a hydrogen or a linear or branched alkyl group having from 1 to 30 carbon atoms, advantageously from 4 to 12 carbon atoms, and(iii) the reaction of a (DPA) compound of formula (I) above with a (PAN) compound of formula (II) above as an agent for the stabilization of a lubricating composition for a conveyor chain subjected to a temperature of at least 120° C.

A phenyl-substituted 1,3,5-triazine compound represented by the general formula (1);wherein Ar1 and Ar2 independently represent substituted or unsubstituted phenyl, naphthyl or biphenylyl group; R1, R2 and R3 independently represent hydrogen atom or methyl group; X1 and X2 independently represent substituted or unsubstituted phenylene, naphthylene or pyridylene group; p and q independently represent an integer of 0 to 2; and Ar3 and Ar4 independently represent substituted or unsubstituted pyridyl or phenyl group. This compound is suitable for an organic electroluminescent device.

Described herein are antipyschotic compounds of formula (I)wherein,A is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S;Alk is (C1-4) alkylene optionally substituted with OH, methoxy, ethoxy, or F;Ar is optionally substituted phenyl, naphthyl, monocyclic heteroaromatic, or bicyclic heteroaromatic;R1 is hydrogen or (C1-4) alkyl optionally substituted with OH, OR3, or OCH2CH2OH,wherein R3 is (C1-2) alkyl;R2 is H, (C1-6) alkyl, halogen, fluorinated (C1-6) alkyl, OR4, SR4, NO2, CN, COR4, CONR5R6, SO2NR5R6, NR5R6, NR5COR4, NR5SO2R4, or optionally substituted phenyl,whereinR4 is hydrogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, or optionally substituted phenyl,R5 and R6 are independently hydrogen, (C1-6) alkyl, or optionally substituted phenyl;Z is one or two substituents independently selected from hydrogen, halogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, OR7, SR7, NO2, CN, COR7, CONR8R9, SO2NR8R9, NR8SO2R7, NR8R9, or optionally substituted phenyl,whereinR7 is hydrogen, (C1-6) alkyl, fluorinated alkyl, or optionally substituted phenyl,R8 and R9 are independently hydrogen, (C1-6) alkyl, or optionally substituted phenyl;and salts, solvates, and crystal forms thereof.Also described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorder, and pharmaceutical formulations of the compounds of formula (I).